Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

More than 1,000,000 patients are being treated with Dupixent globally.1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.